Results 31 to 40 of about 38,234 (213)
Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukemia (BCP-ALL) carries an immunoglobulin- MYC rearrangement (IG-MYC-r).
Simon Bomken +39 more
doaj +1 more source
Aberrant expression of CD79a has been reported in neoplastic cells in peripheral T cell lymphoma, T-cell acute lymphoblastic leukemia and acute myeloid leukemia (especially those with t(8;21)).
Rashpal Singh Flora +2 more
doaj +1 more source
Early T-cell precursor (ETP) lymphoblastic leukemia/lymphoma is a high-risk T lymphoblastic leukemia/lymphoma (T-ALL/LBL) subgroup. We performed a real-world multicenter study to explore the clinical characteristics and prognosis of adolescent and young ...
Jinyan Xiao +17 more
doaj +1 more source
Abstract The serine/threonine Pim kinases are up-regulated in specific hematologic neoplasms, and play an important role in key signal transduction pathways, including those regulated by MYC, MYCN, FLT3-ITD, BCR-ABL, HOXA9, and EWS fusions.
Lin, Ying-Wei +10 more
openaire +4 more sources
ABL oncogene amplification with p16INK4a gene deletion in precursor T‐cell acute lymphoblastic leukemia/lymphoma: Report of the first case [PDF]
AbstractGene amplification is a relatively rare event in hematologic malignancies. The ABL gene on chromosome band 9q34 is a proto‐oncogene and is the well‐known translocation partner of the BCR gene on 22q11 giving rise to t(9;22)(q34;q11), which is the hallmark of chronic myeloid leukemia and is the most common chromosomal abnormality in adult acute ...
Hee-Jin, Kim +4 more
openaire +2 more sources
Exploring downstream pathways of aberrantly activated kinases for targeted leukemia therapy [PDF]
Genetic alterations resulting in uncontrolled protein tyrosine kinases (PTKs) activity are frequently found in leukemia and in human solid cancers. Although the development of small molecule kinase inhibitors has revolutionized therapy for PTKinduced ...
Gasser, Christelle
core +1 more source
Introduction: Cerebrospinal fluid (CSF) infiltration can be identified at diagnosis and during the course of many hematopoietic malignancies, mainly acute leukemia and aggressive non-Hodgking lymphomas (NHL).
GF Bevilacqua +6 more
doaj +1 more source
A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug l-asparaginase [PDF]
l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL). There is wide individual variation in pharmacokinetics, and little is known about its metabolism.
Vaskar Saha +52 more
core +1 more source
ObjectiveThis study aims to compare the characteristics of early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) and non-ETP ALL patients and the outcomes of these patients after allogeneic hematopoietic stem cell transplantation ...
Juan Chen +15 more
doaj +1 more source
Acute lymphoblastic leukemia in infants: 20 years of experience
Objective: To analyze patients younger than 2 years with acute lymphoblastic leukemia, treated in the period between 1990 and 2010 in a state reference center.
Amanda Ibagy +7 more
doaj +1 more source

